首页> 美国卫生研究院文献>PLoS Clinical Trials >Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality
【2h】

Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality

机译:老年人流感疫苗接种:25年随机对照试验的随访。对长期死亡率无影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Influenza vaccination is proven effective in preventing influenza. However, long-term effects on mortality have never been supported by direct evidence. In this study we assessed the long-term outcome of influenza vaccination on mortality in the elderly by conducting a 25-year follow-up study of a RCT on the efficacy of influenza vaccination as baseline. The RCT had been conducted in the Netherlands 5 years before vaccination was recommended for those aged >65 and 17 years before recommending it for those aged >60. The RCT included 1838 community-dwelling elderly aged ≥ 60 that had received an intramuscular injection with the inactivated quadrivalent influenza vaccine (n = 927) or placebo (n = 911) during the 1991/1992 winter. In our follow-up study, outcomes included all-cause mortality, influenza-related mortality and seasonal mortality. Unadjusted and adjusted hazard ratios (HRs) were estimated by Cox regression and sub-hazard ratios (SHRs) by competing risk models. Secondary analyses included subgroup analyses by age and disease status. The vital status up to January 1, 2017 was provided in 1800/1838 (98%) of the cases. Single influenza vaccination did not reduce all-cause mortality when compared to placebo (adjusted HR 0.95, 95% CI 0.85−1.05). Also, no differences between vaccination and placebo group were shown for underlying causes of death or seasonal mortality. In those aged 60–64, median survival increased with 20.1 months (95% CI 2.4–37.9), although no effects on all-cause mortality (adjusted HR 0.86, 95% CI 0.72−1.03) could be demonstrated in survival analysis. In conclusion, this study did not demonstrate a statistically significant effect following single influenza vaccination on long-term mortality in community-dwelling elderly in general. We propose researchers designing future studies on influenza vaccination in the elderly to fit these studies for longer-term follow-up, and suggest age-group comparisons in observational research.Clinical trial registry number: .
机译:流感疫苗被证明可有效预防流感。但是,对死亡率的长期影响从未得到直接证据的支持。在这项研究中,我们通过对RCT进行为期25年的RCT随访研究,评估了流感疫苗接种对老年人死亡率的长期结果,该研究以流感疫苗接种为基线。 RCT在荷兰进行,建议在65岁以上的人群中接种疫苗前5年,在17岁之前的60岁以上人群建议接种前。随机对照试验包括1838名年龄≥60岁的社区居民老年人,他们在1991/1992年冬季接受了肌肉注射灭活的四价流感疫苗(n = 927)或安慰剂(n = 911)。在我们的后续研究中,结果包括全因死亡率,与流感相关的死亡率和季节性死亡率。通过Cox回归估算未调整和调整后的危险比(HRs),并通过竞争风险模型估算亚危险比(SHR)。次要分析包括按年龄和疾病状况进行的亚组分析。截至1800/1838(98%)的病例提供了截至2017年1月1日的生命状态。与安慰剂相比,单次流感疫苗接种并未降低全因死亡率(调整后的HR 0.95,95%CI 0.85-1.05)。同样,未显示出疫苗接种与安慰剂组之间死亡或季节性死亡的根本原因之间的差异。在60-64岁的人群中,中位生存期延长了20.1个月(95%CI为2.4-37.9),尽管在生存分析中并未显示出对全因死亡率的影响(校正后的HR 0.86,95%CI 0.72-1.03)。总而言之,这项研究并未显示出单次流感疫苗接种后对一般社区居民老年人的长期死亡率有统计学意义的影响。我们建议研究人员针对老年人的流感疫苗接种设计未来的研究,以使这些研究适合长期随访,并建议在观察研究中进行年龄组比较。临床试验注册号:

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号